The interaction between endothelial cells and vascular smooth muscle cells (VSMC) plays an important role in regulating cardiovascular homeostasis. Endothelial cells synthesize and release endothelium-derived relaxing factors (EDRFs), including vasodilator prostaglandins, nitric oxide (NO), and endothelium-dependent hyperpolarization (EDH) factors. Importantly, the contribution of EDRFs to endothelium-dependent vasodilatation markedly varies in a vessel size-dependent manner; NO mainly mediates vasodilatation of relatively large vessels, while EDH factors in small resistance vessels. We have previously identified that endothelium-derived hydrogen peroxide ($\text{H}_2\text{O}_2$) is an EDH factor especially in microcirculation. Several lines of evidence indicate the importance of the physiological balance between NO and $\text{H}_2\text{O}_2$/EDH factor. Rho-kinase was identified as the effectors of the small GTP-binding protein, RhoA. Both endothelial NO production and NO-mediated signaling in VSMC are targets and effectors of the RhoA/Rho-kinase pathway. In endothelial cells, the RhoA/Rho-kinase pathway negatively regulates NO production. On the contrary, the pathway enhances VSMC contraction with resultant occurrence of coronary artery spasm and promotes the development of oxidative stress and vascular remodeling. In this review, I will briefly summarize the current knowledge on the regulatory roles of endothelium-derived relaxing factors, with special references to NO and $\text{H}_2\text{O}_2$/EDH factor, in relation to Rho-kinase, in cardiovascular health and disease.

**Key Words:** endothelium, endothelium-derived relaxing factors, nitric oxide, hydrogen peroxide, Rho-kinase

The endothelium plays important roles in modulating the tonus of underlying vascular smooth muscle cells (VSMC) by synthesizing and releasing endothelium-derived relaxing factors (EDRFs), including vasodilator prostaglandins (e.g., prostacyclin), nitric oxide (NO), and endothelium-dependent hyperpolarization (EDH) factors (Fig. 1).(1,2) Since the discovery of endothelium-dependent hyperpolarization in 1988,(11–14) several candidates have been proposed as the nature of EDH factors. Importantly, the contribution of EDRFs to endothelium-dependent vasodilatations markedly varies as a function of vessel size; endothelium-derived NO mainly mediates vasodilatation of relatively large, conduit vessels, while EDH factors that of resistance arteries (Fig. 2).(13) This vessel-size-dependent contribution of NO and EDH factors is well preserved among species, from rodents to humans, in order to maintain a physiological balance between them.(1,2) Endothelial dysfunction is characterized by impaired production and/or action of EDRFs, reflecting the hallmark and potential predictor for atherosclerotic cardiovascular diseases.(15) Various risk factors (e.g., smoking, diabetes mellitus, hypertension, and dyslipidemia) cause endothelial dysfunction, initiating the step toward atherosclerotic cardiovascular diseases.(1,2)

Rho-kinases (Rho-kinase $\alpha$/ROK$\alpha$/ROCK2 and Rho-kinase $\beta$/ROK$\beta$/ROCK1) were identified as the effector of the small GTP-binding protein, RhoA, independently by 3 research groups in 1996. Hereafter, both Rho-kinase $\alpha$/ROK$\alpha$/ROCK2 and Rho-kinase $\beta$/ROK$\beta$/ROCK1 are collectively referred to as Rho-kinase. (1) Accumulating evidence indicates that Rho-kinase plays important roles in the pathogenesis of oxidative stress and cardiovascular diseases. (1,9,16)

In this review, I will briefly summarize the current knowledge on the two endothelium-derived relaxing factors, NO and $\text{H}_2\text{O}_2$/EDH factor, and Rho-kinase in cardiovascular health and disease.

**Physiological Balance between NO and EDH**

EDH factors cause hyperpolarization and subsequent relaxation of underlying VSMC with resultant vasodilatation of small resistance vessels, finely tuning blood pressure and tissue perfusion instantaneously in response to diverse physiological demands. (1,2) As mentioned above, endothelium-derived NO and EDH factors share the important roles in modulating vascular tonus in a distinct vessel size-dependent manner (Fig. 2). In this scope, vasodilator prostaglandins play a small but constant role, independent of vessel size in general. In contrast, NO predominantly regulates the tonus of relatively large conduit vessels (e.g., aorta and epicardial coronary arteries), while the importance of EDH factors increases as vessel size decreases (e.g., small mesenteric arteries and coronary microvessels). (1,2) Thus, EDH-mediated vasodilatation is especially important in microcirculation, where blood pressure and tissue perfusion are critically determined. Moreover, such redundant mechanisms in endothelium-dependent vasodilatations are advantageous for maintaining cardiovascular homeostasis with compensatory interactions. (11–14) Indeed, in various pathological conditions with atherosclerotic risk factors, NO-mediated relaxations are easily impaired, where EDH-mediated responses are fairly preserved or even enhanced to serve as a compensatory vasodilator system. (11–14) Multiple mechanisms appear to be involved in the enhanced EDH-mediated responses in small resistance vessels as discussed later. (15)

**Endothelium-derived $\text{H}_2\text{O}_2$ as an EDH Factor**

**Identification of endothelium-derived $\text{H}_2\text{O}_2$ as an EDH factor.** Several EDH factors appear to exist depending on the vascular bed, vessel size, and species studied, including...
epoxyeicosatrienoic acids, metabolites of arachidonic P450 epoxygenase pathway, electrical communication through gap junctions, and as we demonstrated in 2000, endothelium-derived hydrogen peroxide (H$_2$O$_2$) (Fig. 1). Indeed, endothelium-derived H$_2$O$_2$ at physiologically low concentrations is one of the major EDH factors in mouse and human small mesenteric arteries and human, porcine, and canine coronary arteries. Thus, endothelium-derived H$_2$O$_2$ attracts increasing attention in view of its emerging relevance for cardiovascular disease.

In the clinical settings, it has been repeatedly reported that chronic nitrate therapy has neutral or even harmful effects in patients with cardiovascular diseases and that antioxidant treatments are also ineffective to prevent cardiovascular events. These lines of evidence indicate the importance of the physiological balance between NO and EDH factors in maintaining cardiovascular homeostasis and in curing diseases associated with endothelial dysfunction.

H$_2$O$_2$ is an important physiological signaling molecule serving especially in microcirculation, for blood pressure, coronary microcirculation, and metabolic functions. Reactive oxygen species (ROS) have been considered to be harmful in general because of their highly-damaging effects on cells and tissues and pathological implications in various cardiovascular diseases, including atherosclerosis, hypertension, heart failure, and coronary artery disease. However, as exemplified by endothelium-derived H$_2$O$_2$/EDH factor, a growing evidence has demonstrated that physiological levels of ROS can serve as crucial signaling molecules in health and disease. The following 4 sets of early observations led us to hypothesize that a putative EDH factor might be a non-NO vasodilator substance (likely ROS) derived from endothelial NO synthases (NOSs) system. First, both NO-mediated and EDH-mediated responses are susceptible to vascular injuries caused by various atherosclerotic factors, and conversely, the treatment of those risk factors can restore both responses. Second, it was previously demonstrated that endothelium-derived free radicals exert relaxing or contracting effects in an endothelium-dependent manner in canine coronary arteries. Third, both endothelial NOS (eNOS)-derived NO generation and EDH-mediated responses are dependent on calcium/calmodulin. Fourth, a simple molecule (like NO) rather than complex substances may be favorable in instantaneously modulating vascular tone in response to physiological demands in the body. Finally, in 2000, we were able to demonstrate for the first time that eNOS-derived H$_2$O$_2$ is an EDH factor in mouse mesenteric arteries, using eNOS-knockout (KO) mice. Subsequently, this was also confirmed in other blood vessels, including human mesenteric and coronary arteries, porcine and canine coronary arteries, and piglet pial arterioles.

Endothelial source of H$_2$O$_2$/EDH factor. Endothelium-derived H$_2$O$_2$ could be generated by the dismutation of superoxide anions, which are derived from various sources in the endothelium, including eNOS, NADPH oxidase, mitochondrial electron transport.
Chain, xanthine oxidase, and lipoygenase (Fig. 1). There are 3 NOS isoforms; eNOS (NOS3), neuronal NOS (nNOS, NOS1), and inducible NOS (iNOS, NOS2). Using singly-eNOS-KO, doubly-n/eNOS-KO, and triply-n/i/eNOS-KO mice, we have previously demonstrated that EDH-mediated relaxations are progressively reduced as the number of deleted NOS genes increased. Collectively, these results indicate that the 3 NOSs isoforms compensate each other to maintain H₂O₂-mediated EDH-type relaxations (Fig. 2). Thus, in large conduit vessels, NOSs mainly serve as a NO-generating system to cause soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP)-mediated vascular relaxations, whereas in small resistance vessels, they act as a NO/nGMP-mediated main relaxations. However, in conduit arteries, a recent study has demonstrated the potential regulatory mechanisms underlying the physiologically relevant H₂O₂ in the endothelium. Indeed, local subcellular concentrations at microdomains rather than net cellular concentrations may be critical to determine whether the effects of ROS can be detrimental or beneficial for cellular signaling and co-localization of the source and target of H₂O₂ may help to avoid non-specific harmful oxidations. One good example of this notion is that only a minor increase in ROS caused by caveolar localization of NADPH oxidase-1 in hypertension is enough to interfere with NO-mediated signaling.

**Mode of action of H₂O₂/EDH factor.** Oxidative modification of cGMP-dependent protein kinase G (PKG) is a central mechanism by which H₂O₂ induces hyperpolarization and relaxation of underlying VSMCs, although other modes of action of H₂O₂/EDH factor have also been proposed. Briefly, H₂O₂ induces dimerization of 1α-isoforms of PKG (PKG1α) through an interprotein disulfide bond formation between them to enhance the kinase activity through phosphorylation. The activated PKG1α subsequently stimulates K⁺ channels with resultant hyperpolarization and vasodilation in mouse mesenteric arteries and human coronary arterioles. H₂O₂ also promotes the translocation of PKG1α from cytoplasm to membrane in human and porcine coronary arteries. Such reversible post-translational modification, like phosphorylation, may be favorable for the fine control of vascular tone in response to demand fluctuation in vivo.

**Mechanisms for the dominant role of H₂O₂/EDH factor in microcirculation.** Accumulating evidence has provided the mechanistic insights into vessel size-dependent contribution of NO and H₂O₂/EDH factor. Pretreatment with NO donors attenuates EDH-mediated vasodilation in porcine coronary arteries in vitro and canine coronary microcirculation in vivo and that NO exerts a negative-feedback effect on endothelium-dependent vasodilation through vascular smooth muscle cells (VSMCs).
cGMP-mediated desensitization in canine coronary arteries \textit{ex vivo}\textsuperscript{59–61}. Multiple mechanisms have been proposed for the dominant role of H\textsubscript{2}O\textsubscript{2}/EDH factor in microcirculation (Fig. 3). Among them, cGMP-dependent activation of PKG desensitizes VSMC to H\textsubscript{2}O\textsubscript{2} by inhibiting H\textsubscript{2}O\textsubscript{2}-induced PKG\textsubscript{1a} dimerization, a central mechanism of H\textsubscript{2}O\textsubscript{2}/EDH factor-mediated vasodilatation, and in turn, pharmacological inhibition of sGC sensitizes conduit vessels, but not resistance vessels, to H\textsubscript{2}O\textsubscript{2}-induced vasodilatation in mice.\textsuperscript{62} Furthermore, mouse resistance vessels have less NO production and less antioxidant capacity, predisposing PKG\textsubscript{1a} to be more sensitive to H\textsubscript{2}O\textsubscript{2}-induced activation.\textsuperscript{62,63} Other key players for the dominant role of H\textsubscript{2}O\textsubscript{2}/EDH factor in resistance vessels include endothelial caveolin-1 (a negative regulator of eNOS) and \(\alpha_1\)-subunit of endothelial AMP-activated protein kinase (Fig. 3).\textsuperscript{63,64} In contrast, phosphorylation at Tyr657 of eNOS in response to H\textsubscript{2}O\textsubscript{2} leads to reduction in eNOS activity with resultant reduced NO production.\textsuperscript{65} Taken together, these mechanisms are in line with the widely accepted notion that EDH-mediated responses function as a compensatory vasodilator system when NO-mediated relaxations are compromised.\textsuperscript{11,21,15} It is important to maintain the vessel size-dependent contribution of NO and EDH factors because excessive endothelial NO production by either caveolin-1 deficiency or eNOS overexpression disrupts the physiological balance between NO and H\textsubscript{2}O\textsubscript{2}/EDH factors in endothelium-dependent vasodilation, resulting in impaired cardiovascular homeostasis associated with enhanced nitrative stress in mice \textit{in vivo}.\textsuperscript{11,63,66}

\textbf{Clinical significance of H\textsubscript{2}O\textsubscript{2}/EDH factor.} Endothelium-derived H\textsubscript{2}O\textsubscript{2} plays an important role in blood pressure regulation. Pharmacological inhibition of catalase, which decomposes H\textsubscript{2}O\textsubscript{2} into O\textsubscript{2} and H\textsubscript{2}O, decreases arterial blood pressure associated with enhanced PKG\textsubscript{1a} dimerization \textit{in vivo}.\textsuperscript{57} Moreover, the ‘redox-dead’ knock-in mice of Cys42Ser PKG\textsubscript{1a}, whose mutant PKG\textsubscript{1a} is unable to be activated by H\textsubscript{2}O\textsubscript{2}-induced dimerization due to the deletion in its redox-sensitive sulfur, exhibit markedly impaired EDH-mediated hyperpolarization and relaxation in resistance arteries associated with systemic arterial hypertension.\textsuperscript{155} Furthermore, H\textsubscript{2}O\textsubscript{2} has potent vasodilator properties in coronary resistance vessels and plays important roles in coronary autoregulation,\textsuperscript{125} cardioprotection against myocardial ischemia/reperfusion Fig. 3. Molecular mechanisms of enhanced H\textsubscript{2}O\textsubscript{2}/EDH factor-mediated responses in microvessels. Multiple mechanisms are involved in the enhanced EDH-mediated responses in microvessels. AMPK\(\alpha_1\), \(\alpha_1\)-subunit of AMP-activated protein kinase; CaM, calmodulin; CaMK\(\beta\), Ca\textsuperscript{2+}/CaM-dependent protein kinase \(\beta\); CaMK\(\alpha_2\), Ca\textsuperscript{2+}/CaM-dependent protein kinase II; cGMP, cyclic GMP; Cu\textsubscript{2}Zn-SOD, copper-zinc superoxide dismutase; EDH, endothelium-dependent hyperpolarization; H\textsubscript{2}O\textsubscript{2}, hydrogen peroxide; IP\textsubscript{3}, inositol trisphosphate; I/R, ischemia-reperfusion; K\textsubscript{Ca}, calcium-activated potassium channel; NO, nitric oxide; NOSs, NO synthases; P, phosphorylation; PKG\textsubscript{1a}, 1\textsubscript{a}-subunit of protein kinase G; PLC, phospholipase C; sGC, soluble guanylate cyclase; TRPV4, transient receptor potential vanilloid 4, VSMC; vascular smooth muscle cells.
Clinical Implications for Endothelial Functions (H$_2$O$_2$/EDH)

**Endothelial function tests.** Assessment of endothelial function has been acknowledged as a useful surrogate marker of cardiovascular events in many clinical settings, although it is challenging to accurately assess EDH-mediated responses, especially in humans *in vivo*, because the contribution of EDH factors could be determined only after the blockade of both vasodilator prostaglandins and NO by its definition. (1,2) EDH-mediated vasodilatation can be enhanced to compensate for impaired NO-mediated responses in the early stage of atherosclerotic conditions. (3,4) However, after prolonged exposure to atherosclerotic risk factors, this compensatory role of EDH-mediated responses is finally disrupted to cause metabolic disturbance. (6) Indeed, endothelial dysfunction, as reflected by impaired flow-mediated dilatation (FMD) of the brachial artery or digital reactive hyperemia index (RHI) in peripheral arterial tonometry, is associated with future cardiovascular events in patients with coronary artery disease and one SD decrease in FMD or RHI is associated with doubling of cardiovascular event risk. (6)

H$_2$O$_2$/EDH factor and coronary artery disease. Previous studies focused structural and functional abnormalities of “epicardial” coronary arteries in CAD patients because they are easily visible on coronary angiography and amenable to procedural intervention (*e.g.*, percutaneous coronary intervention). However, those of coronary microvasculature, referred to as coronary microvascular dysfunction (CMD), have recently attracted increased attention due to their unexpectedly high prevalence and significant prognostic impacts in this population. (7) The etiologies of CMD still remain largely unknown and may be heterogeneous, for which several structural (*e.g.*, vascular remodeling, vascular rarefaction, and extramural compression) and functional abnormalities (*e.g.*, endothelial dysfunction, VSMC dysfunction, and microvascular spasm) have been demonstrated. (8,9) Given that H$_2$O$_2$ has potent vasodilator properties in coronary resistance vessels where EDH factors play relatively dominant roles than NO, it is highly possible that impaired H$_2$O$_2$/EDH factor-mediated vasodilatation is involved in the pathogenesis of CMD. Indeed, in eNOS-KO mice, CMD caused by reduced H$_2$O$_2$/EDH factor is substantially involved in the pathogenesis of cardiac diastolic dysfunction. (10) Thus, for the treatment of CAD, it is essential to maintain the physiological balance between NO and H$_2$O$_2$/EDH factor, which notion is supported by the fact that significant negative interactions exist between NO and several EDH factors and that nitrates as NO donors are not beneficial for the treatment of CMD. (11,3,66)

**Lessons from clinical trials targeting NO: it is a time to change our mind.** Although the role of CMD has been implicated in patients with obstructive CAD who underwent successful revascularization, (12) the effects of isosorbide-5-mononitrate were unexpectedly neutral in patients with microvascular ischemia despite successful percutaneous coronary intervention. (3) Besides CAD, recent studies highlighted the high prevalence and pathophysiological relevance of CMD in patients with heart failure with preserved ejection fraction (HFpEF). (13,14) Contrary to the premise that enhancing NO-mediated vasodilatation should exert beneficial effects on patients with HFpEF, the results of systemic and long-term administrations of inorganic nitrates in those patients were disappointing or even harmful in randomized clinical trials. (15) In a recent animal study, genetic ablation of endothelial arginase-1, an inhibitor of NO production, did not improve vasomotor function of resistance arteries in diabetic mice. (16) Similarly, antioxidant therapies for patients with cardiovascular diseases had no benefits. (17) These lines of evidence indicate that we need to change our mind to avoid excessive NO supplementation and to pay more attention to the potential harmful effects of non-specific elimination of ROS by antioxidants. (18,19) Multiple mechanisms may be involved in the failure of antioxidant therapies, including inadequate dose, short treatment duration, and pro-oxidant effects of antioxidants upon supplementation and thus so-called “antioxidant paradox” in clinical trials requires further investigations. (20) An alternative explanation for such “paradox” of NO-targeted therapy may be nitrosative stress induced by an excessive amount of NO, (21,22) again suggesting the importance of physiological balance between NO and EDH factors in endothelium-dependent vasodilatation. Further research is warranted to address how to modulate CMD to improve clinical outcomes of patients with cardiovascular diseases.

Roles of Rho-kinase in the Cardiovascular System

**Molecular regulation of Rho-kinase.** Rho-kinase (ROCKs) is an important downstream effector of the small GTP-binding protein RhoA (Fig. 4). During the past 20 years, significant progress has been made regarding the molecular mechanisms and therapeutic importance of Rho-kinase in cardiovascular medicine. (1,2) The Rho family of small G proteins includes 20 members of ubiquitously expressed proteins, including RhoA, Rac1, and Cdc42. (1,2) Among them, RhoA acts as a molecular switch that cycles between an inactive GDP-bound and an active GTP-bound conformation interacting with downstream targets (Fig. 4). RhoA is activated by the guanine nucleotide exchange factors (GEFs) that catalyze exchange of GDP for GTP and is inactivated by the GTPase activating proteins (GAPs). (23) There are 2 isoforms of Rho-kinase, Rho-kinase α/ROCK1 and α/ROCK2 and Rho-kinase β/ROCK β/ROCK1, which were identified as the effector of Rho and have been shown to play important roles in the pathogenesis of cardiovascular diseases. (24,25) Phosphorylation of myosin light chain (MLC) is crucial for VSMC contraction. MLC is phosphorylated by Ca$^{2+}$/calmodulin-activated MLC kinase (MLCK) and is dephosphorylated by MLC phosphatase (MLCP) (Fig. 4). (26) Agonists bind to G-protein-coupled receptors and induce contraction by increasing both cytosolic Ca$^{2+}$ concentration and ROCK activity through mediating GEF. (27,28) The substrates of ROCK include MLC, myosin phosphatase target subunit (MYPT)-1, ezrin/radixin/moesin family, adducin, phosphatase and tensin homolog, eNOS, Tau, and LIM-kinases (Fig. 4). (29) Currently, functional differences between ROCK1 and ROCK2 have been reported *in vitro*. ROCK1 is specifically cleaved by caspase-3, whereas granzyme B cleaves ROCK2. (27,28)

**Negative interactions between NO and Rho-kinase.** The RhoA/Rho-kinase pathway negatively regulates NO production in endothelial cells, while it enhances contraction of VSMC by MLC phosphorylation through inhibition of MYPT-1 of MLCP and promotes VSMC contraction (Fig. 4). (27,28) Rho-kinase has opposing activities in the regulation of the endothelial barrier function at the cell margins and contractile F-actin stress fibers. (29) Thus, disruption of the endothelial barrier results in increased endothelial permeability, promoting organ damage in various diseases. (26,27,28) The RhoA/Rho-kinase signaling pathway is involved in the mechanotransduction mechanism for the adherence junction strengthening at endothelial contacts. (29) This endothelial mechanosensing is important for endothelial alignment along the flow direction, which contributes to vascular homeostasis. Indeed, a disturbed flow promotes endothelial dysfunction and the development of atherosclerosis. (29) Several studies demonstrated that
NO and Rho-kinase have opposing effects.\(^{99,100}\) Rho-kinase-KO mice showed preserved endothelial functions in a diabetic model.\(^{100}\) Moreover, NO and Rho-kinase exert opposing effects on the phosphorylation of AMP-activated protein kinase in lipid metabolism and the insulin receptor substrate-1 in insulin signaling.\(^{101–103}\) Statins upregulate eNOS by cholesterol-independent mechanisms, involving the inhibition of Rho geranyl-geranylation and hydroxyfasudil reversed hypoxia-induced upregulation of Rho-kinase and eNOS downregulation in human endothelial cells.\(^{104,105}\) In addition, small GTP-binding protein dissociation stimulator (SmgGDS) plays a central role in the pleiotropic effects of statins, independently of the Rho-kinase pathway, through Rac1 degradation (Fig. 4).\(^{106}\) Thus, we need to consider the complex interactions between Rho-kinase and NO signaling for vascular homeostasis in vivo.

**Role of Rho-kinase on vascular reactive oxygen species.**

The balance between oxidants and antioxidants maintains redox status equilibrium in the cardiovascular system.\(^{107}\) The RhoA/Rho-kinase pathway is one of the major intracellular pathways that enhance the expressions of molecules for oxidative stress (NADPH, IL-6, MCP-1, MIF, IFN-\(\gamma\)), thrombosis (PAI-1 and tissue factor), and tissue fibrosis (TGF-\(\beta\)1 and Bcl-2), while the pathway also markedly downregulates eNOS and osteogenesis-related molecules (BMP-2 and osteocalcin) (Fig. 1 and 4).\(^{108–112}\) Oxidative stress by excessive ROS damages mitochondrial proteins and further increase intracellular ROS, thus forming a vicious cycle of ROS augmentation. In addition to ROS generation in mitochondria, several enzymes also generate intracellular ROS, including NADPH that produce \(\text{O}_2^-\) and \(\text{H}_2\text{O}_2\). Importantly, enhanced Rho-kinase activity downregulates eNOS, resulting in impaired endothelial responses to NO and EDH (Fig. 1 and 4).\(^{113}\) eNOS produces NO with resultant production of \(\text{cGMP}\), and NO can react with \(\text{O}_2^-\) to produce peroxynitrite (ONOO\(^-\)). Among ROS, \(\text{H}_2\text{O}_2\) can easily penetrate the cell membrane and act as a second messenger. Peroxiredoxin is regenerated by the antioxidant protein thioredoxin 1 and reduces \(\text{H}_2\text{O}_2\) levels, thus balancing the intracellular redox state.\(^{114}\) The details of the interactions between Rho-kinase and NO/\(\text{H}_2\text{O}_2\) as an EDH factor remain to be fully elucidated in future studies.

---

**Fig. 4.** Role of Rho/Rho-kinase pathway in the pathogenesis of cardiovascular diseases. Rho/Rho-kinase–mediated pathway plays an important role in the signal transduction initiated by many agonists, including angiotensin II (Ang II), serotonin (5-HT), thrombin, endothelin-1 (ET-1), norepinephrine (NE), platelet-derived growth factor (PDGF), adenosine triphosphate (ATP)/adenosine diphosphate (ADP), and urotensin II (Uro II). Through the modulation of its target effectors, Rho-kinase is substantially involved in vascular smooth muscle contraction (via inhibition of myosin phosphatase) and in the pathogenesis of arteriosclerosis (via activation of ERM, adducin, and other effectors). Whereas statins inhibit Rho at its relatively higher concentrations, they simultaneously inhibit pathways mediated by other G proteins, such as Ras and Rac. By contrast, Rho-kinase inhibitors selectively inhibit Rho-kinase pathway. Solid line indicates proven pathway and dashed line proposed pathway. DG, diacylglycerol; MLC, myosin light chain; PKC, protein kinase C; SmgGDS, small GTP-binding protein dissociation stimulator.
Conclusions

This review highlights the potential importance of the physiological balance between NO and H\textsubscript{2}O\textsubscript{2}/EDH factor in a distinct vessel size-dependent manner through the diverse functions of endothelial NOs in maintaining cardiovascular homeostasis. It remains an open question how to improve endothelial functions without affecting the delicate balance between NO and EDH factors. Further characterization and better understanding of endothelium-dependent vasodilations are important to this end, which helps us develop novel therapeutic strategies in cardiovascular medicine. The identification of Rho-kinase as an important mediator of oxidative stress in cardiovascular health and disease provides insight into the development of new therapies. Indeed, accumulating evidence indicates that Rho-kinase is substantially involved in the pathogenesis of a wide variety of cardiovascular diseases, suggesting that it is an important therapeutic target in cardiovascular medicine.

Acknowledgments

This work was supported in part by the grants-in-aid for scientific research from the Japanese Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan, and the grants-in-aid for scientific research from the Japanese Ministry of Health, Labour, and Welfare, Tokyo, Japan. I am deeply grateful to the collaborators at the Mayo Clinic, Kyushu University, and Tohoku University, especially Prof. Paul M. Vanhoutte and Prof. Akira Takeshita for their life-long supports for me. Finally, I would like to greatly appreciate the Society for Free Radical Research JAPAN for giving me a chance for this invited review article to memorize the 2019 Award of the Society.

References

1 Shimokawa H. 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities—from bench to bedside. *Ear Heart J* 2014; 35: 3180–3193.
2 Vanhoutte PM, Shimokawa H, Feeletou M, Tang EH. Endothelial dysfunction and vascular disease—a 30th anniversary update. *Acta Physiol (Oxf)* 2017; 219: 22–96.
3 Feeletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. *Br J Pharmacol* 1988; 93: 515–524.
4 Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. *Br J Pharmacol* 1988; 95: 1165–1174.
5 Shimokawa H, Yasutake H, Fujii K, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. *J Cardiovasc Pharmacol* 1996; 28: 703–711.
6 Matsu T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. *EMBO J* 1996; 15: 2208–2216.
7 Leung T, Chen XQ, Manser L, Lim L. The p160 RhoA-binding kinase ROK alpha is a member of a kinase family and is involved in the reorganization of the cytoskeleton. *Mol Cell Biol* 1996; 16: 5313–5327.
8 Ishizaki T, Maekawa K, Fujisawa K, et al. The small GTP-binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. *EMBO J* 1996; 15: 1885–1893.
9 Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). *Science* 1996; 273: 245–248.
10 Amano M, Ito M, Kimura K, et al. Phosphorylation and activation of myosin by Rho-associated kinase (Rho-kinase). *J Biol Chem* 1996; 271: 20246–20294.
11 Godo S, Sawada A, Saito H, et al. Disruption of physiological balance between nitric oxide and endothelium-dependent hyperpolarization impairs cardiovascular homeostasis in mice. *Arterioscler Thromb Vasc Biol* 2016; 36: 97–107.
12 Urunishi-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteriolar tone in flow-induced dilation of human coronary arteries. *Clin Invest* 1997; 100: 2793–2799.
13 Félotou M, Vanhoutte PM. EDHF: an update. *Clin Sci (Lond)* 2009; 117: 139–155.
14 Ozkor MA, Murrow JR, Rahman AM, et al. Endothelium-derived hyperpolarizing factor determines resting and stimulated forearm vasodilator tone in health and in disease. *Circulation* 2011; 123: 2244–2253.
15 Ohashi J, Sawada A, Nakajima S, Noda K, Takaki A, Shimokawa H. Mechanisms for enhanced endothelium-derived hyperpolarizing factor-mediated responses in microvessels in mice. *Circ J* 2012; 76: 1768–1779.
16 Campbell WB, Gehrenheid D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. *Circ Res* 1996; 78: 415–423.
17 Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an endothelial cytochrome P450 synthase. *Circulation* 2002; 105: 493–497.
18 Griffith TM, Chaytor AT, Edwards DH. The obligatory link: role of gap junctional communication in endothelium-dependent smooth muscle hyperpolarization. *Pharmacol Rev* 2004; 49: 551–564.
19 Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K’ is an endothelium-derived hyperpolarizing factor in rat arteries. *Nature* 1998; 396: 269–72.
20 Matoba T, Shimokawa H, Nakashima M, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. *J Clin Invest* 2000; 106: 1521–1530.
21 Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing factor. *Pflugers Arch* 2010; 459: 915–922.
22 Matoba T, Shimokawa H, Kubota H, et al. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in human mesenteric arteries. *Biochem Biophys Res Comm* 2002; 290: 909–913.
23 Miura H, Hosnjak JJ, Ning G, Saito T, Miura M, Guttermans DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. *Circ Res* 2003; 92: e31–e40.
24 Matoba T, Shimokawa H, Morikawa K, et al. Electron spin resonance detection of hydrogen peroxide as an endothelium-derived hyperpolarizing factor in porcine coronary microvessels. *Arterioscler Thromb Vasc Biol* 2003; 23:

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| BMP-2 | bone morphogenetic protein-2 |
| cGMP | cyclic guanosine monophosphate |
| CMD | coronary microvascular dysfunction |
| EDH | endothelium-dependent hyperpolarization |
| EDRF(s) | endothelium-derived relaxing factor(s) |
| NO | nitric oxide |
| NOS | endothelial nitric oxide synthase |
| GEFs | guanine nucleotide exchange factors |
| H\textsubscript{2}O\textsubscript{2} | hydrogen peroxide |
| MCP-1 | macrophage chemoattractant protein-1 |
| MIF | macrophage inhibitory factor |
| NOX | myosin light chain |
| MLCK | myosin light chain kinase |
| MLCP | myosin light chain phosphatase |
| MYPT-1 | myosin phosphatase target subunit-1 |
| NADPH | nicotinamide adenine dinucleotide phosphate |
| ROS | reactive oxygen species |
| sGC | soluble guanylate cyclase |
| SmgGDS | small GTP-binding protein dissociation stimulator |
| SOD | superoxide dismutase |
| TGF-β1 | transforming growth factor-β1 |
| VSMC | vascular smooth muscle cell |

Conflict of Interest

No potential conflicts of interest were disclosed.
Yada T, Shimokawa H, Hiramatsu O, et al. Hydrogen peroxide, an endogenous endothelium-derived hyperpolarizing factor, plays an important role in coronary autoregulation in vivo. *Circulation* 2003; **107**: 1040–1045.

Yada T, Shimokawa H, Hiramatsu O, et al. Cardioprotective role of endogenous hydrogen peroxide during ischemia-reperfusion injury in canine coronary microcirculation in vivo. *Am J Physiol* 2006; **291**: H1138–H1146.

Yada T, Shimokawa H, Hiramatsu O, et al. Important role of endogenous hydrogen peroxide in pacing-induced metabolic coronary vasodilation in dogs in vivo. *J Am Coll Cardiol* 2007; **50**: 1272–1278.

Liu Y, Babolz AH, Mendoza S, Zhang DX, Gutterman DD. Hydrogen peroxide is the transferase factor mediating flow-induced dilation in human coronary arteries. *Circ Res* 2011; **108**: 566–573.

Félétou M. The Endothelium: Part 2: EDHF-Mediated Responses “The Classical Pathway”. San Rafael, CA: Morgan & Claypool Life Sciences Publisher, 2011.

Russo G, Di Franco A, Lamendola P, et al. Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. *Cardiovasc Drugs Ther* 2013; **27**: 229–234.

Reidell MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. *N Engl J Med* 2015; **373**: 2314–2324.

Takahashi J, Nibai T, Takagi Y, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. *Eur Heart J* 2015; **36**: 228–237.

Golino M, Spera FR, Manfredonia L, et al. Microvascular ischemia in patients with successful percutaneous coronary intervention: effects of ranolazine and isosorbide-5-mononitrate. *Eur Rev Med Pharmacol Sci* 2018; **22**: 6545–6550.

Vanhoutte PM. Endothelium-derived free radicals: for worse and for better. *J Clin Invest* 2001; **107**: 23–25.

Praszyhazna O, Rudyk O, Eaton P. Single atom substitution in mouse protein kinase G eliminates oxidant sensing to cause hypertension. *Nat Med* 2012; **18**: 286–290.

Nakajima S, Ohashi J, Sawada A, Noda K, Fukushima Y, Shimokawa H. Essential role of bone marrow for microvascular endothelial and metabolic functions in mice. *Circ Res* 2012; **111**: 87–96.

Reddi AR, Culotta VC. SOD1 integrates signals from oxygen and glucose to repress respiration. *Cell* 2013; **152**: 224–235.

Holmström KM, Finkel T. Cellular mechanisms and physiological consequences of redox-dependent signalling. *Nat Rev Mol Cell Biol* 2014; **15**: 411–421.

Shimokawa H, Morikawa K. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. *J Mol Cell Cardiol* 2005; **39**: 725–732.

Rubanyi GM, Vanhoutte PM. Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. *Am J Physiol* 1986; **250 (5 Pt 2)**: H1821–H1831.

Nagao T, Illiano S, Vanhouthe PM. Calmodulin antagonists inhibit endothelium-dependent hyperpolarization in the canine coronary artery. *Br J Pharmacol* 1992; **107**: 382–386.

Lacza Z, Puskar M, Kis B, Perciaccante JV, Miller AW, Busija DW. Hydrogen peroxide acts as an EDHF in the piglet pial vasculature in response to bradykinin. *Am J Physiol Heart Circ Physiol* 2002; **283**: H406–H411.

Burgoine JR, Oka S, Ale-Agha N, Eaton P. Hydrogen peroxide sensing and differentially modulates cardiac myocyte nitric oxide synthesis. *Proc Natl Acad Sci U S A* 2011; **108**: 15792–15797.

Shiroto T, Romero N, Sugiyama T, et al. Caveolin-1 is a critical determinant of autophagy, metabolic switching, and oxidative stress in vascular endotheliium. *PloS One* 2014; **9**: e87671.

Lohydevia I, Rath G, Sikkakli B, et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. *Arterioscler Thromb Vasc Biol* 2011; **31**: 2098–2105.

Burgoine JR, Madhani M, Cuello F, et al. Cysteine redox sensor in PKGIIa enables oxidant-induced activation. *Science* 2007; **317**: 1393–1397.

Chidgey J, Fraser PA, Aaronson PI. Reactive oxygen species facilitate the EDHF response in arterioles by potentiating intracellular endothelial Ca²⁺ release, *Free Rad Biol Med* 2016; **97**: 274–284.

Zhang DX, Borbouse L, Gebremedhin D, et al. H₂O₂-induced dilation in human coronary arterioles: role of protein kinase G dimerization and large-conductance Ca²⁺-activated K⁺ channel activation. *Circ Res* 2012; **110**: 471–480.

Dou D, Zheng X, Liu J, Xu X, Ye L, Gao Y. Hydrogen peroxide enhances vasodilatation by increasing dimerization of cGMP-dependent protein kinase type Ia. *Circ Res* 2012; **107**: 1792–1798.

Vanhouthe PM, Zhao Y, Xu A, Leung SW. Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. *Circ Res* 2016; **119**: 375–396.

Bauernsach J, Popp R, Hecker M, Sauer E, Fleming I, Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. *Circulation* 1996; **94**: 3341–3347.

Nishikawa Y, Stepp DW, Chilian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. *Am J Physiol* 2000; **279**: H459–H465.

Olmos L, Mombouli JV, Illiano S, Vanhouthe PM. cGMP mediates the desensitization to bradykinin in isolated canine coronary arteries. *Am J Physiol* 1995; **268 (2 Pt 2)**: H865–H870.

Burgoine JR, Praszyhazna O, Rudyk O, Eaton P. cGMP-dependent activation of protein kinase G precludes disulfide activation: implications for blood pressure control. *Hypertension* 2012; **60**: 1301–1308.

Saito H, Godo S, Sato S, et al. Important role of endothelial caveolin-1 in the protective role of endothelium-dependent hyperpolarization against nitric oxide-mediated nitrative stress in microcirculation in mice. *J Cardiovasc Pharmacol* 2018; **71**: 113–126.

Eshghjafari B, Godo S, Saito T, et al. Endothelial AMP-activated protein kinase regulates blood pressure and coronary flow responses through hyperpolarization mechanism in mice. *Arterioscler Thromb Vasc Biol* 2014; **34**: 1505–1513.

Fleming I. Molecular mechanisms underlying the activation of eNOS. *Pflugers Arch* 2010; **459**: 783–806.

Ikumi Y, Shiroto T, Godo S, et al. Important roles of endothelium-dependent hyperpolarization in coronary microcirculation and cardiac diastolic function in mice. *J Cardiovasc Pharmacol* 2020; **75**: 31–40.

Crea F, Lanza G, Camici P. Mechanisms of coronary microvascular dysfunction. In: *Coronary Microvascular Dysfunction*. Springer Milan, Italy 2014; 31–47.

Chadderon SM, Belck JT, Bader L, et al. Temporal changes in skeletal muscle capillary responses and endothelial-derived vasodilators in obesity-related insulin resistance. *Diabetes* 2016; **65**: 2249–2257.

Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis. *J Am Heart Assoc* 2015; 4: pii: e002270.

Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. *Circulation* 2014; **129**: 2518–2527.

Suda A, Takahashi J, Hao K, et al. Coronary functional abnormalities in patients with angina and non-obstructive coronary artery disease. *J Am Coll Cardiol* 2019; **74**: 2350–2360.

Al-Lamee R, Thompson D, Debbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled
trial. *Lancet* 2018; 391: 31–40.
73 Crea F, Baiery Merz CN, Beltrame JF, et al. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. *Eur Heart J* 2016; 38: 473–477.
74 Dryer K, Gajjar M, Narang N, et al. Coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. *Am J Physiol 2018; 314: H1033–H1042."
75 Shah SJ, Lam CSP, Svedlund S, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFPEF. *Eur Heart J* 2018; 39: 3349–3450.
76 Borlaug BA, Anstrom KJ, Lewis GD, et al. Effect of inorganic nitrite vs placebo on exercise capacity among patients with heart failure with preserved ejection fraction: the INDIE-HFPEF randomized clinical trial. *JAMA 2018; 320: 1764–1773."
77 Chennupati R, Meens MJ, Janssen BJ, et al. Deletion of endothelial arginine 1 does not improve vasomotor function in diabetic mice. *Physiol Rep 2018; 8: e13717."
78 Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in patients with heart failure with preserved ejection fraction: 1764–1773."
79 Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. *J Biol Chem 2001; 276: 8719–8722."
80 Shimokawa H, Satoh K. Light and dark of reactive oxygen species for vascular integrity via cyclophilin A. *Nature 2012; 485: 512–516."
81 Schiattarella GG, Altamirano F, Tong D, et al. Involvement of rho p21 in the GTP-activation of the Rho-kinase in cardiovascular medicine. *Trends Pharmacol Sci 2001; 22: 337–342."
82 Bernards A. GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila. *Biochem Biophys Acta 2003; 1603: 47–82."
83 Sosnovy AP, Somlyo AV. Signal transduction and regulation in smooth muscle. *Nature 1994; 372: 231–236."
84 Hirata K, Kikuchi A, Sasaki T, et al. Involvement of rho p21 in the GTP-enhanced calcium ion sensitivity of smooth muscle contraction. *J Biol Chem 1992; 267: 8719–8722."
85 Gong MC, Iizuka K, Nixon G, et al. Role of guanine nucleotide-binding proteins—rass-family or trimeric proteins or both—in Ca2+ sensitization of smooth muscle. *Proc Natl Acad Sci U S A 1996; 93: 1340–1345."
86 Nishioka T, Shohag MI, Amano M, Kaihuichi A. Developing novel methods to search for substrates of protein kinases such as Rho-kinase. *Biochem Biophys Acta 2015; 1854 (10 Pt B): 1663–1666."
87 Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nat Cell Biol 2001; 3: 339–345."
88 Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breaud J. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. *J Exp Med 2005; 201: 465–471."
89 van Nieuw Amerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ, van Hinsbergh VW. Involvement of Rho-kinases in endothelial barrier maintenance. *Arterioscler Thromb Vasc Biol 2007; 27: 2332–2339."
90 Bell RD, Winkler EA, Singh J, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature 2012; 485: 512–516."
91 Jiang Y, Chen HY, Scherer PE. The role of lipids and lipoproteins in atherosclerosis: modulation by Rho-kinase. *J Biol Chem 2001; 276: 8719–8722."
92 Haddad S, Durieux ME. Perioperative care of patients with heart failure. *Anesth Analg 2007; 104: 152–157."
93 Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nat Cell Biol 2001; 3: 339–345."
94 Sebbagh M, Hamelin J, Bertoglio J, Solary E, Breaud J. Direct cleavage of ROCK II by granzyme B induces target cell membrane blebbing in a caspase-independent manner. *J Exp Med 2005; 201: 465–471."
95 van Nieuw Amerongen GP, Beckers CM, Achekar ID, Zeeman S, Musters RJ, van Hinsbergh VW. Involvement of Rho-kinases in endothelial barrier maintenance. *Arterioscler Thromb Vasc Biol 2007; 27: 2332–2339."
96 Bell RD, Winkler EA, Singh J, et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature 2012; 485: 512–516."
97 Berk BC. Atheroprotective signaling mechanisms activated by steady laminar flow in endothelial cells. *Circulation 2008; 117: 1082–1089."
98 Nigro P, Abe J, Berk BC. Flow shear stress and atherosclerosis: a matter of site specificity. *Antioxid Redox Signal 2011; 15: 1405–1414."
99 Zhou Q, Liao JK. Rho-kinases: an important mediator of atherosclerosis and vascular disease. *Curr Pharm Des 2009; 15: 3108–3115."
100 Yao L, Chandra S, Toque HA, et al. Prevention of diabetes-induced arginase activation and vascular dysfunction by Rho-kinases (ROCK) knockout. *Cardiovasc Res 2013; 97: 509–519."
101 Noda K, Godo S, Saito H, Tsutsui M, Shimokawa H. Opposing roles of nitric oxide and Rho-kinase in lipid metabolism in mice. *Tohoku J Exp Med 2015; 235: 171–183."
102 Noda K, Nakajima S, Godo S, et al. Rho-kinase inhibition ameliorates metabolic disorders through activation of AMPK pathway in mice. *PLoS One 2014; 9: e10446."
103 Begum N, Sandu OA, Ito M, Loehmann SM, Smolenski A. Active Rho kinase (ROK-α) associates with insulin receptor substrate-1 and inhibits insulin signaling in vascular smooth muscle cells. *J Biol Chem 2002; 277: 6214–6222."
104 Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. *Arterioscler Thromb Vasc Biol 2001; 21: 1712–1719."
105 Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. *Circulation 2002; 106: 57–62."
106 Tanaka S, Fukumoto Y, Nochioka K, et al. Statins exert the pleiotropic effects through small GTP-binding protein dissociation stimulator upregulation with a resultant Rac1 degradation. *Arterioscler Thromb Vasc Biol 2013; 33: 1591–1600."
107 Shao D, Oka S, Brady CD, Haendeler J, Eaton P, Sadoshima J. Redox modification of cell signaling in the cardiovascular system. *J Mol Cell Cardiol 2012; 52: 550–558."
108 Hirashima H, Shimokawa H, Hattori T, et al. Long-term inhibition of Rho-kinase suppresses angiostatin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. *Circ Res 2003; 93: 767–775."
109 Hattori T, Shimokawa H, Hirashima M, et al. Long-term treatment with a specific Rho-kinase inhibitor suppresses cardiac allograft vasculopathy in mice. *Circ Res 2004; 94: 46–52."
110 Funakoshi Y, Ichiki Y, Shimokawa H, et al. Rho-kinase mediates angiostatin II-induced monocyte chemotactic protein expression in rat vascular smooth muscle cells. *Hypertension 2001; 38: 100–104."
111 Takeda I, Ichiki T, Tokunou T, et al. Critical role of Rho-kinase and MEK/ERK pathways for angiostatin II-induced plasminogen activator inhibitor type-1 gene expression. *Arterioscler Thromb Vasc Biol 2001; 21: 868–873."
112 Ohnaka K, Shimoda S, Nawata H, et al. Pivatavastin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. *Biochem Biophys Res Commun 2001; 287: 337–342."
113 Cohen RA, Adachi T. Nitric-oxide-induced vasodilatation: regulation by physiologic s-glutathiolation and pathologic oxidation of the sarcoplasmic endoplasmic reticulum calcium ATPase. *Trends Cardiovasc Med 2006; 16: 109–114."
114 Wu C, Parrott AM, Fu C, et al. Thioridoxin 1-mediated post-translational modifications: reduction, transnitrosylation, denitrosylation, and related proteomics methodologies. *Antioxid Redox Signal 2011; 15: 2565–2604."

H. Shimokawa et al.